Shamburg News · 8-K filed Nov 10, 2026, 8:00 AM EST

PepGen Reports Q3 2026 Results and Positive 10 mg/kg FREEDOM2-DM1 Phase 2 Data

PEPG · PepGen Inc.

  • Earnings
  • Other event
  • Other
  • Materiality: high

On November 10, 2026, PepGen Inc. reported financial results for the quarter ended September 30, 2026, with a net loss of $19.4 million, or $(0.28) per basic and diluted share, compared with $18.0 million, or $(0.52) per share, a year earlier. The company also announced positive topline Phase 2 FREEDOM2-DM1 results at the 10 mg/kg cohort, showing a mean splicing correction of 46.5%, and reported $104.8 million in cash, cash equivalents and marketable securities as of September 30, 2026. The company furnished an updated presentation on the 10 mg/kg MAD cohort data as Exhibit 99.3.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 8.01, 9.01, accession 0001193125-26-454469.

Written from the filing by Shamburg Markets. Figures are as reported by the company.